FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 03:44:13 2024-06-14 pm EDT | ||
| 7.25 EUR | +4.02% |
|
| Current month | +47.66% | ||
| 1 month | +50.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 7.25 | +4.02% |
| 24-06-13 | 6.97 | -2.52% |
| 24-06-12 | 7.15 | +4.23% |
| 24-06-11 | 6.86 | -7.30% |
| 24-06-10 | 7.4 | +3.79% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 03:44 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SB1M1H |
| ISIN | DE000SB1M1H2 |
| Date issued | 2020-06-17 |
| Strike | 428.6 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 1.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.87 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.19 € |
| Spread % | 2.53% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
